Maruho Co Ltd - Company Profile
Powered by 
All the data and insights you need on Maruho Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Maruho Co Ltd Strategy Report
- Understand Maruho Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Maruho Co Ltd (Maruho) is a pharmaceutical company that researches, develops, produces, and distributes dermatological products. Its product portfolio includes an array of prescription drugs, medical devices and other skincare products. The company also offers products for the treatment of infectious diseases, ophthalmological diseases, ear nose throat disorders, musculoskeletal disorders, central nervous system (CNS) disorders, and cardiovascular, gastrointestinal, and other diseases. Maruho offers prescription drugs in various forms such as ointments, creams, solution, lotions, injections, and gels. The company has manufacturing facilities in Japan, Germany, and the US. Maruho is headquartered in Osaka, Japan.
Headquarters
Japan
Address
1-5-22 Nakatsu, Kita, Osaka, 531-0071
Website
www.maruho.co.jp
Telephone
81 6 63718876
No of Employees
1,547
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$704.7M
Maruho Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Drugs: | Astat |
| Agent for Asthma | Actosin |
| Agent for Keratosis Including Psoriasis Vulgaris | Asthmolysin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with AOB Pharma for both appearance and pruritus (itch). The license is for all indications treated by the B244 platform. |
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Evommune, Inc to exclusively develop and commercialize EVO756 in Japan. |
| 2023 | Contracts/Agreements | In August, the company entered into a licensing agreement with Medical Corporation for the treatment of hyperhidrosis. |
Competitor Comparison
| Key Parameters | Maruho Co Ltd | Galderma SA | Rohto Pharmaceutical Co Ltd | Noevir Holdings Co Ltd | Lee's Pharmaceutical Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Switzerland | Japan | Japan | Hong Kong |
| City | Kita | Zug | Osaka-Shi | Kobe-Shi | HongKong |
| State/Province | Osaka | - | Osaka | Hyogo | - |
| No. of Employees | 1,547 | 5,700 | 7,176 | 1,368 | 1,060 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Koichi Takagi | Chairman | Executive Board | - | - |
| Atsushi Sugita | Director; President; Chief Executive Officer | Executive Board | 2020 | - |
| Takashi Kitagawa | Director; Senior Corporate Officer- Japan Business Operations | Executive Board | - | - |
| Yasuhiko Kito | Director; Senior Corporate Officer- Research & Development, Reliability Assurance & Medical Affairs | Executive Board | - | - |
| Masahiro Akatsuka | Director; Senior Corporate Officer- Global Business Development & Drug Discovery Research | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer